THE ROLE OF SERUM GOLGI BODY GLYCOPROTEIN 73 IN THE DIAGNOSIS OF DIFFERENT TYPES OF LIVER CANCER

Liang Di^*, Jing Ding, Xiaofei Zhao 

Department of General Surgery, Beijing You’an Hospital, Capital Medical University, Beijing 100069, PR China

Objective: To explore the role of serum Golgi body glycoprotein 73 (GP73) in the diagnosis of different types of liver cancer. 

Methods: A total of 106 cases of serum samples from 55 hepatocellular carcinoma (HCC) and 51 intrahepatic cholangiocarcinoma (ICC) patients admitted to our hospital between September 2018 and October 2019 were selected retrospectively as subjects for observation, and another 24 healthy patients with normal physical examinations during the same period were selected as the control group. The sensitivity, specificity, accuracy, and levels of GP73 and alpha-fetoprotein (AFP) in serum samples of patients with liver cancer were observed. 

Results: The detection rate of GP73 was compared with that of pathology in different HCC patients. Among the HCC patients, 29 were positive and 17 were negative. Among the ICC patients, 21 were positive and 17 were negative. The detection rate of AFP was compared with that of pathology. Among the HCC patients, 23 were positive and 16 were negative. Among the ICC patients, four were positive and 16 were negative. The sensitivity, specificity, and accuracy of GP73 in serum samples of different types of liver cancer patients were analyzed. The sensitivity and accuracy of GP73 in the ICC patients were 65.6% and 74.5%, respectively, which were significantly higher than those of the AFP test (12.5% and 39.2%, P<0.05). The concentrations of GP73 and AFP in serum samples from the HCC patients were 203.6±136.5 ng/mL and 578.2±39.1 g/L respectively, significantly higher than those of the ICC patients (137.9±101.9 ng/mL, 38.1±19.3 g/L, P<0.05). Serum concentrations of GP73 and AFP in the ICC patients were significantly higher than those in the control group (58.3±52.6 ng/mL, 11.2±9.0 g/L, P<0.05). 

Conclusion: In this study, GP73 was found to have a superior diagnostic effect in patients with different types of liver cancer. However, in clinical practice, a combination of multiple diagnostic methods is recommended.